PER

0.00%

10.0¢ percheron therapeutics limited

Anp Board to bring home the bacon..ROI, page-14

First 14 Last

Share
Profile

Follow
kpkg

4,149 Posts.

01/02/17

10:45

Post #: 22280063
Share

Originally posted by itsagas ↑

It's a real shame that others on the Innate thread appreciate my posts..eg Pete 70...

This article just out from Tom Richardson from Mötley Fool today...really does justify Diamond and hid Board by doing things by the Book...

"Shares in Aussie biotech hopeful Innate Immunotherapeutics Ltd (ASX: IIL) have gone into orbit today despite the company revealing a quarterly cash flow statement that hardly inspires evangelical-like confidence in the future.

For the quarter ending December 31 2016 it delivered a net operating cash loss of $1.78 million, with just $6 million of cash left on its balance sheet at the end of the period.

What must be exciting investors is the potential of what the company claims are its unique drugs that could be used for the treatment of patients suffering from multiple sclerosis. It’s a condition that attacks a patient’s immune system and Innate Immunotherapeutics currently has a Phase II B clinical trial underway to part test its MIS416 drug’s efficacy in treating patients with secondary progressive multiple sclerosis.

Despite the business having nothing in the way of operating revenues the market is now ascribing it a valuation around $173 million, after shares rocketed 50% to $1.17 today.

Mysterious price action

On January 27 the stock hit a high of $1.83 only to close at 78 cents just one trading day later on January 30 in some wild price action that has already attracted the attention of the regulator in terms of an ASX price query.

The trading action is also seeing relatively heavy volumes which makes the price action all the more mysterious, with the most likely explanation that it is being driven by day traders seeking to make quick profits.

For long-term investors it looks a business to watch from the sidelines and not just because of the huge share price swings increasing the likelihood of a visit to the burns clinic.

Anyone considering an investment should note that the company is currently is still at a relatively early investment stage, with just one product at Phase II trial status. This means it probably has expensive and time consuming Phase III trials ahead of it before it could seek any commercial approval to sell its drugs.

Evidently with multiple hurdles to jump, no revenues, and significant costs ahead, it looks an extremely speculative investment prospect and one to watch from the sidelines in my opinion.

Of course if it does ever get approval for its drugs it will be great news for potential patients and the company’s investors, although that seems a long way off for now."

Expand

I don't doubt that the data for iil (if any exists of a scientific nature )is incredibly flimsy .
However Anp with all its scientific published data has achieved jackshit
So what exactly is your point beyond ramping the unrampable?

ANP Price at posting: 3.8¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The market's shrugged at China's stimulus measures all year. Why is this one different?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

There are more pages in this discussion • 72 more messages in this thread...

First 14 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $90.15M

Open	High	Low	Value	Volume
10.5¢	10.5¢	10.0¢	$47.27K	463.5K

Buyers (Bids)

No.	Vol.	Price($)
3	319942	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	86442	3

View Market Depth

No.	Vol.	Price($)
3	319942	0.100
3	113179	0.099
1	13000	0.098
2	130927	0.097
1	10004	0.096

Price($)	Vol.	No.
0.105	86442	3
0.110	290000	4
0.115	601850	5
0.120	275642	8
0.125	65000	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

PER (ASX) Chart

Anp Board to bring home the bacon..ROI, page-14

ACCC seeks Olam divestments before it can buy Namoi Cotton

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Anp Board to bring home the bacon..ROI, page-14

Top Stories

ACCC seeks Olam divestments before it can buy Namoi Cotton

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News